PathoGenetix, Inc. said has signed Sparton Corp. (NYSE: SPA) as the design and manufacturing partner for the Resolution Microbial Genotyping System.
Under the terms of the agreement, Sparton will conduct design for manufacture and pilot production of a limited number of pre-commercial instruments for the Resolution System, which is slated for commercial availability in the fourth quarter of 2014.
The Resolution System is the first commercial application of PathoGenetix´s proprietary genome sequence scanning technology.
Sparton is a premier partner in the design as well as full production manufacture of class I, II, and III instruments for highly specialized medical, biotechnology, and life science technologies.
PathoGenetix is a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. Learn more at http://www.pathogenetix.com.
Sparton, now in its 114th year, is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, field service, and refurbishment. Its website is at http://www.sparton.com.